We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$386M
AUM Growth
-$41.2M
Cap. Flow
+$640K
Cap. Flow %
0.17%
Top 10 Hldgs %
95.45%
Holding
21
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$816K

Top Sells

Rank Stock Value
1
CLSD
Clearside Biomedical
CLSD
+$105K
2
PHGE icon
BiomX
PHGE
+$71.5K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$9.8B
$94.5M 24.48%
2,449,183
– –
CVRX icon
2
CVRx
CVRX
$78.3M
$52M 13.46%
4,103,430
– –
RAPP
3
Rapport Therapeutics
RAPP
$2.27B
$44.3M 11.48%
2,498,051
– –
MGTX icon
4
MeiraGTx Holdings
MGTX
$1.17B
$40.4M 10.47%
6,641,064
– –
CTNM
5
Contineum Therapeutics
CTNM
$576M
$29M 7.51%
1,979,173
– –
PRCT icon
6
Procept Biorobotics
PRCT
$1.26B
$28.8M 7.46%
357,939
– –
LEGN icon
7
Legend Biotech
LEGN
$3.93B
$26.5M 6.86%
814,586
– –
NMRA icon
8
Neumora Therapeutics
NMRA
$321M
$19.6M 5.08%
1,849,445
– –
XNCR icon
9
Xencor
XNCR
$1.71B
$17.2M 4.45%
748,062
– –
NBTX
10
Nanobiotix
NBTX
$1.94B
$16.1M 4.18%
5,623,816
– –
FATE icon
11
Fate Therapeutics
FATE
$294M
$5.58M 1.44%
3,379,064
– –
ARWR icon
12
Arrowhead Research
ARWR
$12.1B
$4.65M 1.21%
247,598
– –
RLYB icon
13
Rallybio
RLYB
$90.1M
$3.49M 0.9%
454,545
– –
VOR icon
14
Vor Biopharma
VOR
$1.38B
$1.19M 0.31%
53,733
– –
NNOX icon
15
Nano X Imaging
NNOX
$73.2M
$1.14M 0.3%
158,852
– –
LAB icon
16
Standard BioTools
LAB
$294M
$546K 0.14%
311,967
– –
LYEL icon
17
Lyell Immunopharma
LYEL
$337M
$527K 0.14%
+41,166
New +$816K
ACET icon
18
Adicet Bio
ACET
$77.3M
$351K 0.09%
22,780
– –
PHGE icon
19
BiomX
PHGE
$1.67M
$70.7K 0.02%
5,098
-5,024
-50% -$71.5K
SENS icon
20
Senseonics Holdings Inc
SENS
$409M
$28.6K 0.01%
2,731
– –
CLSD
21
DELISTED
Clearside Biomedical
CLSD
– –
-5,499
Closed -$105K

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q4 2024 Portfolio in Review

As of Q4 2024, Johnson & Johnson held 21 positions worth $386M, down 9.6% from $427M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Johnson & Johnson's Q4 2024 filing shows 1 new, 1 reduced and 1 closed positions. Its largest new stake was Lyell Immunopharma: 41,166 shares worth $527K. The largest sale was Clearside Biomedical, an estimated $105K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's largest Q4 2024 buy was Lyell Immunopharma: 41,166 shares worth $527K.
  • Johnson & Johnson's biggest Q4 2024 reduction was BiomX, cutting an estimated $71.5K.
  • Johnson & Johnson fully exited Clearside Biomedical in Q4 2024, selling an estimated $105K.
  • Johnson & Johnson's ten largest holdings make up 95% of its $386M portfolio in Q4 2024.
  • Johnson & Johnson opened 1 new position and closed 1 in Q4 2024.
  • Johnson & Johnson's portfolio value fell 9.6% quarter-over-quarter to $386M.

Based on Johnson & Johnson's 13F filing for Q4 2024, filed 13 Feb 2025.